文献速递炎症性肠病

ENTERPRET:对维多珠单抗早期无应答的溃疡性结肠炎患者进行剂量优化的随机对照试验

ENTERPRET: A Randomized Controlled Trial of Vedolizumab Dose Optimization in Patients With Ulcerative Colitis Who Have Early Nonresponse.
PubMed 文献 · Clin Gastroenterol Hepatol · 2023-11-10

ENTERPRET是一项4期开放标签随机对照试验,纳入第5周药物清除率高(血清浓度<50 μg/mL)且第6周对标准维多珠单抗治疗无应答的中重度溃疡性结肠炎患者。第6周起108例患者随机接受标准剂量或剂量优化方案,第30周标准组18.9%与优化组14.5%达到内镜下改善,临床缓解分别为9.4%与9.1%。结论认为早期无应答且高清除率患者可能不需要剂量优化。

要点

  • 第6周无应答者中86.5%存在高药物清除率。
  • 第30周内镜下改善:标准组18.9% vs 优化组14.5%。
  • 两组安全性事件发生率相似。

核心结论

  • 在早期无应答且高药物清除率的溃疡性结肠炎患者中,维多珠单抗剂量优化可能不需要。
  • 部分患者无论接受何种剂量均从持续治疗中获益。

研究设计与样本

  • 4期开放标签随机对照试验,纳入中重度溃疡性结肠炎患者。
  • 第5周高药物清除率(血清浓度<50 μg/mL)且第6周对标准维多珠单抗无应答者,按1:1随机接受标准剂量(300 mg每8周)或剂量优化方案(第6周600 mg后300 mg每4周;或第6周600 mg后600 mg每4周,依据第5周血清浓度)。
  • 278例入组患者中132例(47.5%)第6周有临床应答;自第6周起108例接受标准(n=53)或剂量优化(n=55)治疗。

主要发现

  • 第30周内镜下改善:标准组10例(18.9%)vs 剂量优化组8例(14.5%)。
  • 第30周临床缓解:标准组5例(9.4%)vs 剂量优化组5例(9.1%)。
  • 第30周临床应答:标准组17例(32.1%)vs 剂量优化组17例(30.9%)。
  • 两组安全性事件发生率相似。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Patients with ulcerative colitis (UC) may experience nonresponse to biologics, possibly as a result of low drug exposure. This trial assessed the efficacy of dose optimization in patients with UC who have early nonresponse to vedolizumab and high drug clearance. METHODS: ENTERPRET was a phase 4, open-label, randomized, controlled trial that included patients with moderate to severe UC who had high drug clearance at week 5 (serum concentration, <50 μg/mL) and nonresponse to standard vedolizumab treatment at week 6. At week 6, eligible patients were randomized 1:1 to receive standard dosing (300 mg every 8 weeks) or dose-optimized vedolizumab (600 mg at week 6, then 300 mg every 4 weeks; or 600 mg at week 6, then 600 mg every 4 weeks [based on week 5 serum concentration]). The primary end point was endoscopic improvement at week 30. RESULTS: Of 278 enrolled patients, 132 (47.5%) had a clinical response at week 6. From week 6, 108 patients received standard (n = 53) or dose-optimized vedolizumab (n = 55); among patients with nonresponse at week 6, 86.5% had high drug clearance. At week 30, 10 patients (18.9%) who received standard vedolizumab had endoscopic improvement vs 8 patients (14.5%) who received dose-optimized vedolizumab. Five patients (9.4%) who received standard vedolizumab had clinical remission at week 30 vs 5 patients (9.1%) who received dose-optimized vedolizumab; clinical response was observed in 17 (32.1%) and 17 patients (30.9%), respectively. Safety event rates were similar among treatment groups. CONCLUSIONS: In patients with early nonresponse and high drug clearance, vedolizumab dose optimization is probably not required. A proportion of patients benefited from continued treatment irrespective of the dose received. CLINICALTRIALS: gov: NCT03029143.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Jairath V, Yarur A, Osterman MT, et al. ENTERPRET: A Randomized Controlled Trial of Vedolizumab Dose Optimization in Patients With Ulcerative Colitis Who Have Early Nonresponse. Clin Gastroenterol Hepatol. 2023. PMID: 37951560. doi:10.1016/j.cgh.2023.10.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。